Of the 3 deaths 2 occurred at 1 location and the third at another. The 2 deaths from cardiac events will be thrown out in terms of review for putting this back on the market. Two deaths at one clinic tends to indicate problems at the clinic in my mind. They were just being very conservative by pulling the drug immediately. It would be interesting to see the data on all incidents, locations and outcomes.